Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
35 hedge funds and large institutions have $238M invested in Verona Pharma in 2020 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 7 increasing their positions, 4 reducing their positions, and 3 closing their positions.
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
75% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 4
25% more funds holding
Funds holding: 28 → 35 (+7)
12% more capital invested
Capital invested by funds: $213M → $238M (+$25.7M)
0.4% more ownership
Funds ownership: 8.22% → 8.62% (+0.4%)
18% less call options, than puts
Call options by funds: $85K | Put options by funds: $104K
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$8.41M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$5.46M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$1.87M |
| 4 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$227K |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$180K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$6.93M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.8M |
| 3 |
WS
Wedbush Securities
Los Angeles,
California
|
-$211K |
| 4 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$77K |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$45.9K |
VRNA Hedge Fund Activity: Q4 2020 in Review
35 of the 5,665 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q4 2020, worth a combined $238M — up 12% from $213M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new VRNA positions and 3 closed out — a net gain of 8 holders — while 7 added to existing stakes and 4 trimmed.
The largest buyer was Wellington Management Group, opening a new position worth an estimated $8.41M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $6.93M sold.
- 35 institutional investors held Verona Pharma (VRNA) as of Q4 2020, up from 28 in Q3 2020.
- Funds reported $238M of Verona Pharma stock for Q4 2020, up 12% quarter-over-quarter.
- 11 funds opened new Verona Pharma positions in Q4 2020 and 3 closed out, a net change of +8 holders.
- The largest Verona Pharma buyer in Q4 2020 was Wellington Management Group, an estimated $8.41M added.
- The largest Verona Pharma seller in Q4 2020 was Foresite Capital Management III, an estimated $6.93M sold.
Based on aggregated 13F filings for Q4 2020.